MDS Pharma Services Strengthens Therapeutic Focus on Respiratory and Metabolic Disorders
News May 27, 2008
MDS Pharma Services has named two experienced medical professionals to lead its late stage clinical trial management activities related to respiratory ailments and metabolic disorders.
Dr. Bernard Tisserand and Dr. Jonny L. Salyer have been named Executive Medical Directors for Respiratory Disorders and Metabolic Disorders, respectively. These therapeutic areas represent serious global public health concerns and are key areas of focus for MDS Pharma Services' customers.
Respiratory disorders include conditions such as asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and community acquired pneumonia (CAP), while metabolic disorders include diabetes, dyslipidemia, obesity and metabolic syndrome, which are defined as a cluster of conditions that damage the cardiovascular system.
In addition to respiratory and metabolic disorders, other areas of therapeutic focus for MDS Pharma Services include oncology, vaccines, and diseases of the cardiovascular and central nervous systems.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE